Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants

Lisa L Weyandt
Danielle R Oster
Marisa E Marraccini
Bergrjot Gyda
Gudmundsdottir
Bailey A Munro
Brynheld Martinez Zavras
Ben Kuhar
Department of Psychology, University of Rhode Island, Kingston, RI, USA

Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattentiveness, hyperactivity, and impulsivity that cause functional impairment. Recent research indicates that symptoms persist into adulthood in the majority of cases, with prevalence estimates of approximately 5% in the school age population and 2.5%–4% in the adult population. Although students with ADHD are at greater risk for academic underachievement and psychosocial problems, increasing numbers of students with ADHD are graduating from high school and pursuing higher education. Stimulant medications are considered the first line of pharmacotherapy for individuals with ADHD, including college students. Although preliminary evidence indicates that prescription stimulants are safe and effective for college students with ADHD when used as prescribed, very few controlled studies have been conducted concerning the efficacy of prescription stimulants with college students. In addition, misuse of prescription stimulants has become a serious problem on college campuses across the US and has been recently documented in other countries as well. The purpose of the present systematic review was to investigate the efficacy of prescription stimulants for adolescents and young adults with ADHD and the nonmedical use and misuse of prescription stimulants. Results revealed that both stimulant and stimulant medications, including lisdexamfetamine dimesylate, methylphenidate, amphetamines, and mixed-amphetamine salts, are effective at reducing ADHD symptoms in adolescents and adults with ADHD. Findings also suggest that individuals with ADHD may have higher rates of stimulant misuse than individuals without the disorder, and characteristics such as sex, race, use of illicit drugs, and academic performance are associated with misuse of stimulant medications. Results also indicate that individuals both with and without ADHD are more likely to misuse short-acting agents than long-acting agents. These findings have implications for intervention, prevention, and future research.

Keywords: ADHD symptomatology, pharmacotherapy, nonmedical stimulant use, lisdexamfetamine, methylphenidate, amphetamine

Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity that cause functional impairment.1 Previously, ADHD was believed to be primarily a disorder of childhood that would be outgrown with the onset of puberty. Recent research, however, indicates that symptoms persist into adulthood in the majority of cases, with prevalence estimates of approximately 5% in the school age population and 2.5%–4% in the adult population.1–4 Academic problems are prevalent among children and adolescents with ADHD and are associated with inattention and difficulty remaining seated, following directions, and completing assignments.5 In addition, children...
and adolescents with ADHD often demonstrate disruptive, defiant, and hostile behavior.\textsuperscript{6,7} Given these academic and behavioral difficulties, children and adolescents with ADHD are more likely than their non-ADHD peers to receive lower grades, fall behind academically, receive special education services, repeat grades, and drop out of high school and are less likely to pursue college.\textsuperscript{5,6} Research suggests, however, that the symptoms of ADHD are often manifested differently in adolescence compared with in childhood. For example, symptoms of hyperactivity tend to decrease in adolescence relative to childhood and instead may be manifested as symptoms of cognitive or internal restlessness.\textsuperscript{9-11} Adolescents with ADHD, however, continue to demonstrate similar levels of impairment as younger children with ADHD, including academic underachievement and difficulties with peers and social relationships, as well as various high-risk behaviors, including reckless driving and sexual behavior and substance use.\textsuperscript{12}

Despite these impairments, students with ADHD are increasingly graduating from high school and attending college.\textsuperscript{13} However, information is lacking concerning the exact prevalence of ADHD among college students, due to privacy protection for students with disabilities under the Americans with Disabilities Act of 1990 and because many college students who meet diagnostic criteria for ADHD may not have been diagnosed with the disorder.\textsuperscript{14,15} Therefore, more information is sorely needed regarding the prevalence of the disorder in the college population and its impact on student functioning. Several investigations have examined the prevalence of ADHD and the functioning of college students with ADHD symptomatology, most of which have relied on student self-report. For example, Weyandt et al\textsuperscript{16} conducted the first study assessing ADHD symptomatology among college students and found that approximately 2.5\%-8.7\% of participants reported significant ADHD symptoms, depending on the criteria employed. More recent estimates are similar to those of Weyandt et al, indicating that approximately 2\%-10\% of college students have significant ADHD symptoms and that approximately 50\% of students who receive disability services do so because of ADHD.\textsuperscript{15,17-19}

In terms of the academic and psychosocial functioning of college students with ADHD, Norwalk et al\textsuperscript{20} found that students with ADHD had greater difficulty with college adjustment and poorer study habits and study skills than students without the disorder. Similarly, Shaw-Zirt et al\textsuperscript{21} found that college students with ADHD, matched with non-ADHD peers on age, sex, and grade point average (GPA) (a measure of academic performance), reported poorer academic, social, and emotional adjustment than non-ADHD participants. Other studies have revealed that college students with ADHD tend to have lower GPAs, higher rates of academic probation, and poorer test-taking strategies and are less likely to graduate from college.\textsuperscript{2,22-24} Self-reported psychological distress also appears to be more common among college students with ADHD than among those without the disorder, including poorer self-esteem and increased levels of depression and anxiety.\textsuperscript{21,25-27} Collectively, these findings indicate that students with ADHD and elevated ADHD symptomatology are beset by various challenges in the college environment. To improve the outcomes of college students with ADHD, proper identification of the disorder is crucial so that effective prevention and intervention strategies may be developed and implemented.

**Medical and nonmedical use of prescription stimulants**

Pharmacotherapy is the primary treatment option for children, adolescents, and adults with ADHD, including college students.\textsuperscript{28,29} US Food and Drug Administration (FDA)-approved medications for ADHD include 1) stimulants such as methylphenidate (MPH) (eg, Ritalin [Novartis International AG, Basel, Switzerland], Concerta [Janssen Pharmaceuticals Inc., Titusville, NJ, USA]), dextroamphetamine (D-AMP) (eg, Adderall [Shire plc, Dublin, Ireland], Dexedrine [GlaxoSmithKline plc, London, UK]), and lisdexamfetamine dimesylate (LDX) (eg, Vyvanse [Shire Inc., Wayne, PA, USA]), a prostimulant; and 2) nonstimulants (eg, atomoxetine, [Strattera; Eli Lilly and Company, Indianapolis, IN, USA]).

Nonstimulants (eg, atomoxetine) have been demonstrated to be safe and effective for improving ADHD symptoms among children, adolescents, and adults.\textsuperscript{30-33} Nonstimulants have been found to be effective for individuals who do not respond to stimulants and have also been recommended for treating patients with ADHD who have comorbid substance use disorder (SUD). Nonstimulants, unlike stimulants, primarily affect the norepinephrine neurotransmitter system rather than the dopaminergic system and consequently have a lower potential for abuse than stimulant medications. Stimulant medications, however, remain the first line of pharmacotherapy for individuals with ADHD.\textsuperscript{28,29,32} An extensive body of literature attests that stimulant medication, when used as prescribed, is safe and efficacious for improving attention and decreasing hyperactivity and impulsivity symptoms.\textsuperscript{34-42} Although individuals with ADHD may greatly benefit from prescription stimulant medication, given their abuse potential when not taken as prescribed, prescription stimulants have been classified as schedule II medications by the FDA. A schedule II classification indicates that although
the medication has been approved for medical use, it has a high potential for abuse, which, in turn, may lead to physiological and/or psychological dependence.43

Numerous studies have documented that the nonmedical use of prescription stimulants, defined here as the use of stimulant medication in the absence of a valid prescription and use of prescription stimulants other than as prescribed, is a growing problem on college campuses, and college students typically report that stimulant medication is easy to obtain on campus.44–52 Indeed, large numbers of students claim to have engaged in the nonmedical use of prescription stimulants, which is reflected in lifetime prevalence rates of prescription stimulant misuse ranging from 5% to nearly 34% of students.53,54 Researchers have speculated that this increase may, in part, be explained by increasing numbers of college students receiving stimulant medication treatment for ADHD who may be distributing their medication to their peers, who may, in turn, misuse it.44,49 Due to the significant health risks associated with the nonmedical use of prescription stimulants, this behavior poses a serious public health issue.55 Consequently, studies have attempted to elucidate the characteristics of prescription stimulant misuse as well as risk and protective factors associated with this behavior.

The most commonly reported and the most strongly endorsed reason for taking prescription stimulants nonmedically is to improve attention and alertness while studying, taking exams, and writing papers: ie, cognitive and academic enhancement.44,45,49,52,53 Research has also identified several risk factors for stimulant misuse, including demographic variables such as sex, ethnicity, and psychological risk factors, such as depressive symptomatology and symptoms of inattention. The identification of malleable predictors such as the academic and psychosocial functioning of students is particularly important for prevention and intervention strategies for prescription stimulant misuse.56–58

**Purpose of the present study**

Given the positive association between psychological factors, ADHD symptoms, and the nonmedical use of prescription stimulants, and that college students report misusing stimulants primarily to enhance their cognitive and academic functioning, it is highly plausible that, by doing so, students are trying to compensate for the struggles they encounter in the college environment. In fact, some researchers have hypothesized that college students may be using prescription stimulants nonmedically as a coping strategy to treat ADHD symptoms: ie, to “self medicate”.49,57 Although preliminary evidence indicates that prescription stimulants are safe and effective for college students with ADHD when used as prescribed, very few controlled studies have been conducted on the efficacy of prescription stimulants for college student functioning specifically.37 The question that arises, then, is whether the medical use of prescription stimulants leads to reductions in symptoms and improved academic and psychosocial outcomes. Further, is the medical use of prescription stimulants associated with increased nonmedical use of these medications? What is the scope of prescription stimulant misuse among college students? Are certain types of medications associated with greater potential for misuse than others? Answers to these questions will greatly inform both the treatment of ADHD among college students and prevention and intervention efforts aimed at reducing the nonmedical use of prescription stimulants on college campuses.

The present study attempted to answer these questions by conducting a systematic review of the literature concerning studies that investigated 1) the efficacy of prescription stimulants for adolescents and adults, including college students, with ADHD and 2) the nonmedical use and misuse of prescription stimulants.

**Methods**

**Search and retrieval**

A systematic literature review was conducted according to Okoli and Schabram’s59 eight-step guide. Accordingly, all researchers were trained in the protocol for searching and identifying relevant articles. Although the first study to identify stimulant misuse was conducted in 2000 by Babcock and Byrne,46 a substantial number of studies addressing stimulant misuse appeared in 2002. Therefore, we attempted to identify and retrieve all empirical studies published after 2002 that examined the efficacy of stimulants and nonstimulants and stimulant misuse with adolescents and adults. The search and retrieval process included a comprehensive search of the following bibliographic databases: PsycINFO, PsycARTICLES®, MEDLINE, and ScienceDirect. Keywords and eligibility criteria were established separately for each subject. In order to identify and retrieve empirical studies that examined the efficacy of stimulants among adolescents and adults, the following keywords were used: “efficacy” + “stimulants”, “efficacy” + “Ritalin”, “efficacy” + “Adderall”, “efficacy” + “Concerta”, “ADHD” + “Ritalin”, “ADHD” + “Adderall”, and “ADHD” + “Concerta”. Keywords used to identify research examining the efficacy of nonstimulants and prostimulants among adolescents and adults included the following: “efficacy” + “nonstimulants”, “efficacy” + “Strattera”, “efficacy” + “Vyvanse”, and “efficacy” + “prostimulant”. Finally, keywords used to identify research examining stimulant misuse among
adolescents and adults were: “prescription stimulant” + “misuse”, “prescription stimulant” + “illicit”, “methylphenidate” + “misuse”, “methylphenidate” + “illicit”, “prescription stimulants” + “nonmedical”, and “methylphenidate” + “nonmedical”.

Eligibility criteria
Studies for all search subjects were selected for review based on the following criteria.

1. The study was published in English.
2. The study was published no earlier than 2002.
3. The study included a minimum sample size of 20 subjects.
4. The study used an original dataset (meta-analyses and reviews were excluded).
5. The study was relational, experimental, or quasiexperimental.
6. The study could be conducted worldwide.
7. The sample included adolescents (ie, participants with a mean age of ≥12 years) and/or adults. Note that studies including both children and adolescents were included if the mean age of participants was ≥12 years. Studies that did not report the participants’ mean age and included samples with a majority of participants aged <12 years were excluded.
8. The sample included human subjects only and included no special groups except for persons with ADHD and learning disabilities.
9. The study used only FDA-approved medication for ADHD.
10. Eligibility criteria were established specifically for research examining the efficacy of stimulants, prostimulants, and nonstimulants.
11. The sample included a control group (guanfacine studies were excluded, as well as studies examining efficacy of nicotinic agonists).

Results
The search process resulted in identifying 2,103 sources, of which 76 met eligibility criteria. Specifically, nine studies examined the efficacy of LDX, 14 explored the efficacy of MPH, three assessed the efficacy of amphetamine (AMPH), three explored the efficacy of both MPH and AMPH in adolescents and adults, and 47 examined stimulant misuse among adolescents and adults. Although included in the initial search process, no studies examining the efficacy of nonstimulants met eligibility criteria for the present review.

Efficacy of prostimulants for adolescents and adults
As seen in Table 1, all of the included studies (n=9) demonstrated a significant improvement in the measured outcomes from LDX compared with placebo. Six of the nine included studies reported effect sizes, all of which (based on Cohen’s estimates of small, medium, and large) reported medium to large LDX-related effects for improvement in ADHD and related symptoms. Although the majority of studies examined LDX effects among adults, only one study examined its efficacy among a sample of adolescents. Specifically, Findling et al reported that at varying doses (30, 50, and 70 mg/day), LDX was more effective at treating ADHD than placebo. Regarding adults with ADHD, improvements from LDX have been reported for quality of life, performance productivity, and executive function. Large effects from LDX on improved executive function were also demonstrated in college students with and without ADHD. Furthermore, LDX was associated with reduced ADHD symptoms compared with placebo in a sample of college students and two different samples of adults. Although higher doses of LDX related to greater improvement in the reduction of ADHD symptoms in two studies, in one study differences between doses were not observed. The maintenance of efficacy of LDX compared with placebo during a 2-week randomized withdrawal phase was also demonstrated to be effective in a sample of adults with ADHD. Finally, findings suggest that LDX may be effective for treating individuals with comorbid ADHD and depression or SUD and in reducing ADHD symptoms.

The most common side effects reported by participants in studies investigating the efficacy of LDX included a decreased appetite, weight loss, dry mouth, insomnia, nausea, diarrhea, dizziness, headache, nasal congestion, feeling jittery, and anxiety. Mild to moderate adverse treatment-related effects were generally reported by 5% or fewer treatment group participants and included insomnia, tachycardia, irritability, fatigue, increased blood pressure/hypertension, upper respiratory tract infections, anxiety, decreased libido, and dyspnea. No deaths were reported in any of the studies. The results of most LDX studies led to the conclusion that the drug has a safety profile consistent with previous studies and other long-acting stimulants.

Efficacy of MPH and AMPH for adolescents and adults
Although research examining the efficacy of LDX is in its early stages, numerous studies have examined the efficacy
Table 1: Studies investigating the efficacy of lisdexamfetamine dimesylate (LDX) for adolescents and adults (N=9)

| Reference | Measures | Doses of LDX | N  | Groups | Design | Conclusion | Effect sizes |
|-----------|----------|--------------|----|--------|--------|------------|-------------|
| 61        | Clinician-determined ADHD-RS total score | 30, 50, or 70 mg/day | N=420 | Adults with ADHD | Double-blind, placebo-controlled study | All three LDX doses were more effective than placebo in the treatment of ADHD, with improvement in ADHD symptoms observed within 1 week. No differences between doses were observed | \( d = 0.73, 0.89, \text{ and } 0.99 \) for 30, 50, and 70 mg doses, respectively |
| 35        | BRIEF-A scales (GEC, index, and clinical subscales) | 30, 50, or 70 mg/day | N=161 | Adults with ADHD and EF deficits aged 18–55 years | Randomized, double-blind, placebo-controlled study | Individually optimized LDX intake was associated with improvement in EF | \( d \text{ for GEC } = 0.74 \) |
| 66        | AIM-A (quality of life measure) and CGI-S/CGI-I | 30–70 mg/day | N=42 | Adults with ADHD aged ≥ 18 years | 4-week, open-label, dose-optimization phase followed by a randomized, double-blind, multicenter, placebo-controlled, 2-way crossover phase | Individually optimized LDX intake associated with increased quality of life | Not reported |
| 67        | ADHD-RS-IV, CGI-S | 30, 50, or 70 mg/day | N=16 | Adults with ADHD aged 18–55 years | 3-week open-label phase at a stable LDX dose, 6-week double-blind, randomized, withdrawal phase on treatment with LDX (same dose) or placebo | Individually optimized LDX dose intake demonstrated maintenance of efficacy compared with placebo during a 2-week randomized withdrawal phase | Not reported |
| 37        | Self-report rating scales of functioning and direct assessment of ADHD symptoms, verbal learning/memory, and adverse side effects | 30, 50, or 70 mg/day | N=50 | College students with and without ADHD aged ≥ 18 years | Double-blind, placebo-controlled, crossover study | LDX intake was associated with large reductions in ADHD symptoms and improved EF compared with placebo. Higher LDX doses associated with greater symptom reduction and EF improvement LDX more effective than placebo at reducing ADHD symptoms; higher doses related to greater improvement; response not affected by prior pharmacotherapy | Effect of LDX on ADHD symptoms: partial \( \eta^2 = 0.30 \) (inattention/memory problems) and 0.41 (hyperactivity/restlessness) and EF (global EF); partial \( \eta^2 = 0.26 \) \( d \text{ for effect size of LDX relative to placebo ranged from } -0.9 \text{ to } 2.0, \text{ with stronger effects for greater baseline symptom severity } \) |
| 62        | ADHD-RS, CGI-I and CGI-S | 30, 50, or 70 mg/day | N=420 | Adults with ADHD aged 18–55 years | 4-week, randomized, double-blind, placebo-controlled, parallel-group, forced-dose titration study | LDX at all doses was more effective than placebo in treating ADHD symptoms, with a trend for greater rates of improvement with increasing doses | Not reported |
| 65        | ADHD-RS-IV, CGI-I, and YQOL-R | 30, 50, or 70 mg/day | N=314 | Adolescents with ADHD aged 13–17 years | 4-week, forced-dose titration, double-blind study | LDX was effective at treating ADHD symptoms among individuals with and without comorbid depressive or substance use disorders. No dosage effects were reported | \( d \text{ for LDX efficacy for participants without a history of depression } = 0.58 \text{ (CI } 0.37, 1.53) \text{ and with a history of depression } = 0.86 \text{ (CI } 0.57, 1.14) \) |
| 63        | ADHD-RS, CGI-I | 30, 50, or 70 mg/day | N=53 | Adults with ADHD aged 18–55 years | Randomized, double-blind, placebo-controlled, forced-dose titration study | Not reported |
of MPH, AMPH, and mixed amphetamine salts (MAS). The included research studies examined the effects of these stimulants among samples of adolescents (n=5), one of which also included children, and adults (n=15) (see Table 2). The vast majority of studies (n=14) specifically examined the effects of some form of MPH, whereas three studies examined MAS, and the remaining studies (n=3) examined a combination of MPH and MAS or AMPH. Regardless of the medication examined, all of the included studies reported statistically significant positive effects for stimulant medication compared with placebo, and effect sizes ranging from small to large based on Cohen’s estimates of effect size. A total of 14 out of 20 included studies reported effect sizes. Of the studies reporting effect sizes for positive effects from stimulant medication, most effect sizes ranged from medium to large, with two studies reporting small to medium effects.

Studies assessing the effects of MPH, dextroamphetamine extended release (d-MPH-ER), MPH long-acting or extended release (MPH-ER), multilayer-release MPH, and MAS, including triple-bead MAS and MAS extended release (MAS-ER), have demonstrated reductions in ADHD symptoms among adult samples.

Regarding the effective dose for improvements in ADHD symptoms, doses of MPH-ER of 36–108 mg/day and 40–80 mg/day have been shown to be effective. Similarly, two studies reported that higher doses of MPH-ER and d-MPH-ER were more effective than lower doses at reducing ADHD symptoms among adults with ADHD. Among adolescents, higher doses, compared with lower doses, of d-MPH-ER and MAS-ER have also been shown to relate to improvement of ADHD symptoms. Rösler et al, however, reported that even at low to moderate doses (10–60 mg/day), MPH-ER was effective at reducing ADHD symptoms and that these effects were sustained during a 24-week follow-up.

In addition to ADHD symptoms, studies have shown that MPH and MPH-ER may improve cognition and emotional symptoms, and triple-bead MAS may enhance executive function.
### Table 2: Studies investigating the efficacy of methylphenidate (MPH) and/or amphetamine for adolescents and adults (N=20)

| Reference | Measures                                                                 | Doses of medication | Types of medication | N      | Age group                                  | Design                                      | Conclusion                                                                                           | Effect sizes |
|-----------|--------------------------------------------------------------------------|---------------------|---------------------|--------|--------------------------------------------|---------------------------------------------|------------------------------------------------------------------------------------------------------|--------------|
| 34        | Adult ADHD Investigator System Report Scale                               | 36, 54, 72, 90, or 108 mg/day | OROS-MPH            | N=226  | Adults with ADHD aged 18–65 years          | Randomized, placebo-controlled, double-blind, parallel group, dose-escalation study | OROS-MPH at 36–108 mg/day was effective at decreasing ADHD symptoms                                      | Not reported |
| 68        | Digit span tasks, Raven’s Progressive Matrices, TOVA, decision-making tasks | 15 mg (10 mg or 20 mg if low/high body weight) | MPH                  | N=58   | Adults aged ≥18 years; 32 with ADHD, 26 non-ADHD | Randomized, double-blind, placebo-controlled study | MPH intake associated with enhanced cognitive performance, nonspecific to ADHD                       | d=0.74 for backward version of digit span task for MPH and placebo conditions, d=0.53 for forward version of digit span task for MPH and placebo conditions |
| 83        | CGI-I, Adult ADHD Investigator System Report Scale                         | Up to 1.3 mg/kg/day | OROS-MPH            | N=141  | Adults with ADHD aged 19–60 years          | Double-blind, randomized, 6-week, placebo-controlled, parallel design | MPH was effective at reducing symptoms of inattention and hyperactivity/impulsivity relative to placebo | Not reported |
| 79        | Wender–Utah Rating Scale, Adult ADHD Problem Behaviors, Hamilton Anxiety Rating Scale, Beck Depression Inventory, Wechsler Adult Intelligence Scale, Conners’ Continuous Performance Test, stop signal computerized task | 10 mg 3 times daily then 15 mg 3 times daily | MPH                  | N=30   | Adults with ADHD aged ≥18 years            | Double-blind, placebo-controlled, crossover trial | MPH effective at improving ADHD symptoms compared with placebo                                         | Not reported |
| 40        | ADHD-RS-IV                                                                | 40, 60, or 80 mg/day | MPH-LA              | N=725  | Adults with ADHD aged 18–60 years          | 40-week, double-blind, placebo-controlled study | MPH-LA at doses of 40–80 mg/day decreased ADHD symptoms compared with placebo at the end of the 9-week double-blind phase of the study | d of all MPH-LA three dose levels combined was 0.55 for DSM-IV ADHD-RS (0.55, 0.47, and 0.64 for MPH-LA 40, 60, and 80 mg, respectively) and was 0.39 for SDS total score (0.47, 0.25, and 0.43 for MPH-LA 40, 60, and 80 mg, respectively) |
| 69        | CGI-I, CGI-I-S, and CAARS self-report and observer rated                  | Participants were titrated to optimal effect over 1–3 weeks followed by 2 weeks of treatment on a stable dose | MLR MPH              | N=50   | Adults with ADHD aged 18–60 years          | Double-blind, placebo-controlled, crossover study | Daily MLR MPH intake resulted in significant decrease in ADHD symptoms compared with placebo | Effect size for global improvement =0.90 (95% CI 0.43–1.36), effect size for the CAARS-A ADHD Index =0.53 (95% CI 0.05–0.99) |

(Continued)
| Reference | Measures | Doses of medication | Types of medication | N | Age group | Design | Conclusion | Effect sizes |
|-----------|----------|---------------------|---------------------|---|-----------|--------|------------|--------------|
| 80        | ADHD-RS, semistructured and structured diagnostic interviews for ADHD and other disorders | 0.5–1.0 mg/kg/day | MPH | N=45 | Adults with ADHD aged ≥18 years | Randomized, placebo-controlled, double-blind, crossover trial | MPH demonstrated to be effective at reducing ADHD symptoms compared with placebo | Not reported |
| 70        | CAARS    | 18, 36, or 72 mg/day | OROS-MPH | N=402 | Adults with ADHD aged 18–63 years | Double-blind, randomized, placebo-controlled, parallel-group, fixed-dose trial at 51 sites | OROS-MPH intake resulted in decrease in ADHD symptoms compared with placebo. Larger doses were associated with greater symptom reduction | Not reported |
| 78        | ADHD self-report and parent report ratings, objective measures of inattention and hyperactivity/impulsivity during driving performance and neuropsychological tasks | 72 mg of OROS-MPH, 30 mg of se-AMPH-ER | OROS-MPH, se-AMPH-ER | N=35 | Adolescents with ADHD aged 16–19 years | Randomized, double-blind, placebo-controlled, crossover study | MPH was associated with reductions in ADHD symptoms compared with placebo MAS-ER treatment for 4 weeks was associated with significant improvements in ADHD symptoms compared with placebo | d=1.41 for the difference between MPH and placebo^{b} |
| 72        | Structured diagnostic interview for DSM-IV (SCID-I and Kiddie SADS-E) | 1.1 mg/kg/day | MPH | N=146 | Adults with ADHD aged 19–60 years | Double-blind, randomized, placebo-controlled study | MPH was associated with reductions in ADHD symptoms compared with placebo MAS-ER treatment for 4 weeks was associated with significant improvements in ADHD symptoms compared with placebo | d=0.78 for differences in ADHD symptomatology between MAS-ER and placebo groups |
| 73        | ADHD-RS, CGI-I | 10, 20, 30, and 40 mg/day | MAS-ER, Adderall XR | N=287 | Adolescents with ADHD aged 13–17 years | 4-week, randomized, multcenter, double-blind, placebo-controlled, parallel-group, forced-dose titration study | MAS was more effective in treating adult ADHD symptoms and improving executive functioning and QOL than placebo | d=0.53 for 20 mg, 0.49 for 30 mg, and 0.83 for 40 mg of d-MPH-ER |
| 74        | ADHD-RS, CGI-I | 20, 30, or 40 mg/day | d-MPH-ER | N=184 | Adults with ADHD aged 18–60 years | Multcenter, randomized, fixed-dose, double-blind, placebo-controlled | Higher doses of d-MPH-ER were associated with increased improvement in ADHD symptoms compared with placebo | d=0.53 for 20 mg, 0.49 for 30 mg, and 0.83 for 40 mg of d-MPH-ER |
| 81        | ADHD-RS-IV, CGI-I, Brown Attention Deficit Disorder Scale, and AIM-A | Starting dose 12.5 mg | Triple-bead MAS | N=272 | Adults with ADHD aged 18–55 years | 7-week, randomized, double-blind, multcenter, placebo-controlled, parallel-group, dose-optimization study | MAS was more effective in treating adult ADHD symptoms and improving executive functioning and QOL than placebo | 24.5 versus placebo 5.7; P<0.0001, least-squares mean difference, 18.8 for performance and daily functioning subscale of AIM-A QOL between triple-bead MAS and placebo |
| 75        | ADHD-RS-IV, CGI-I and CGI-S, parent completed Weiss Functional Impairment Scale | 10, 20, 25–30 mg/day | Long-acting d-MPH-ER and ER-MAS | N=56 | Children and adolescents with ADHD aged 9–17 years, mean age 11.7 years | 8-week, double-blind, crossover study comparing d-MPH-ER and MAS-ER | d-MPH-ER and MAS-ER were associated with significant reductions in ADHD symptoms. Improvement was associated with larger doses rather than type of medication | r²= 0.59 and 0.46, respectively, for dose-related decreases in total and hyperactive symptom scores that did not differ by stimulant. r²=0.11 for decreases of inattention symptoms that did not differ by stimulant |
| Study | Design | Intervention | N   | Population | Outcome Measures | Key Findings |
|-------|--------|--------------|-----|------------|------------------|--------------|
| 71    | Double-blind, randomized, placebo-controlled study with parallel-group design conducted at 10 sites | MPH-ER | 162 | Adults with ADHD aged ≥18 years | MPH-ER was more effective than placebo at treating ADHD symptoms in adults, based on both self- and investigator ratings | $d=0.59$ for differences between MPH-ER vs placebo. $d=0.68$ was reported for attention difficulties. Effects were also reported for hyperactivity $d=0.51$ and hyperactivity/impulsivity $d=0.46$. $d=0.39$ for overall ADHD symptoms. Significant treatment effects in favor of MPH-ER were found: inattention ($d=0.41$), hyperactivity (0.30), hot temper (0.33), affective lability (0.19), emotional overreactivity (0.45), disorganization (0.31), impulsivity (0.27). |
| 76    | Multicenter, double-blind, randomized, placebo-controlled, 24-week study with parallel-group design | MPH-ER | 249 | Adults with ADHD aged ≥18 years | MPH-ER treatment in low to moderate doses was effective at reducing ADHD symptoms; effectiveness sustained at a 24-week follow-up | $d=0.39$ for overall ADHD symptoms. Significant treatment effects in favor of MPH-ER were found: inattention ($d=0.41$), hyperactivity (0.30), hot temper (0.33), affective lability (0.19), emotional overreactivity (0.45), disorganization (0.31), impulsivity (0.27). |
| 77    | Randomized, multicenter, 24-week, double-blind, placebo-controlled study | MPH-ER | 363 | Adults with ADHD aged ≥18 years | MPH-ER was associated with improved emotional symptoms as well as obsessive–compulsive symptoms and problems with self-concept | $d=0.37$ for low MPH-ER treatment of inattention, hyperactivity, and impulsivity. Effects for the ITT and PP populations =0.30 and 0.46, respectively, for obsessive–compulsive symptomatology and 0.29 and 0.40 for self-concept. |
| 82    | Randomized, placebo-controlled trial | MAS-ER | 255 | Adults with ADHD aged ≥18 years | MAS-ER was effective at reducing ADHD symptoms, with effects lasting for up to 12 hours at a time. Symptom reduction was greatest for highest dose for those with severe symptoms | $d$ for MAS-ER =0.8 |
| 84    | Multisite study, 1-week washout phase, an open-label dose titration phase lasting up to 4 weeks, a 2-week double-blind phase consisting of a randomized comparison of an OROS-MPH vs placebo, and 8-week open-label follow-up safety phase of OROS-MPH | OROS-MPH | 177 | Adolescents with ADHD aged 13–18 years | OROS-MPH (individually titrated) was found to significantly reduce ADHD symptoms among adolescents compared with placebo. | Not reported |
| Reference | Measures | Doses of medication | Design | Age group | Conclusion | Effect sizes |
|-----------|----------|---------------------|--------|-----------|------------|--------------|
| Weyandt et al | Go/no-go task measuring inhibition and the Delayed Matching-to-Sample task (nonexecutive visual memory) | 72 mg OROS-MPH, 30 mg Adderall XR | Randomized, double-blind, placebo-controlled study | Adolescents with ADHD aged 16–19 years | Intake of both OROS-MPH and AMPH-ER was associated with improved neuropsychological functioning compared with placebo | Not reported |
| Notes: Article did not report exact type of effect size or calculations; article did not report exact type of effect size, but based on calculations we interpreted it as Cohen’s d. |

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ADHD-RS, ADHD Rating Scale; ADHD-RS-IV, ADHD Rating Scale IV; AIM-A, ADHD Impact Module for Adults; CAARS, Conners’ Adult Attention Deficit Disorder Scale; CAARS:S:L, Conners’ Adult ADHD Rating Scale: Self-report: Long; CGI-I, Clinical Global Impression-Improvement; CGI-S, Clinical Global Impression-Severity; CI, confidence interval; d, Cohen’s d; d-MPH-ER, dexmethylphenidate extended release; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; MAS, mixed amphetamine salts; MAS-eR, extended release; MPH, methylphenidate; MPH-ER, methylphenidate extended release; MPH-LA, methylphenidate long acting; QOL, quality of life; SADS-E, Schedule for Affective Disorders and Schizophrenia - Epidemiologic version; SDS, Sheehan Disability Scale; SCID-I, Structural Clinical Interview for DSM-IV; se-AMPH-ER, extended-release amphetamine salts; TOVA, test of variables of attention; WRAADDS, Wender–Reimherr Adult Attention Deficit Disorder Scale; XR, extended release.

For example, Rösler et al reported on a multicenter 24-week study and found that among a sample of adults with ADHD, taking MPH-ER was associated with improvement in emotional symptoms, obsessive–compulsive symptoms, and problems with self-concept. Among adolescents, one study reported that within a sample of 35 adolescents, those taking either OROS-MPH or amphetamine extended release (AMPH-ER) (Adderall XR) demonstrated improved neuropsychological functioning compared with those taking placebo. Finally, MPH-ER and AMPH-ER have been demonstrated to be equally effective at improving symptoms among male and female adolescents with ADHD.

Regarding side effects in studies investigating the efficacy of D-AMP and MPH, participants most commonly reported decreased appetite, weight loss, headache, insomnia, abdominal pain, dizziness, nervousness, emotional lability, and dry mouth. Approximately half of the studies (n=12) found that a majority of participants reported at least one side effect; however, mild to moderate adverse treatment-related effects were generally reported by ≤5% treatment group participants and included decreased weight, insomnia, tachycardia, palpitation, irritability, fatigue, increased blood pressure/hypertension, and anxiety. No deaths were reported in any of the studies. The results of most stimulant studies led to the conclusion that the drug has a safety profile consistent with previous research.

**Stimulant misuse among adolescents and adults**

The efficacy of prescription stimulants among adolescents and adults with ADHD has been well documented, but the effects of these medications among populations without ADHD are unclear. Despite a lack of empirical evidence of stimulant effectiveness in individuals without ADHD, numerous studies have documented the misuse of prescription stimulants among college students without the disorder. Indeed, the present review retrieved more research studies pertaining to stimulant misuse (n=47) than the combined number of included studies assessing the efficacy of LDX, MPH, AMP, and MAS combined (see Table 3). The primary foci of the retrieved studies examining stimulant misuse varied. For example, some studies reported on prevalence rate estimates, others examined characteristics of individuals most susceptible to stimulant misuse, and others reported primarily on student opinions, such as ethical implications of stimulant misuse. Most of the studies, however, reported on some combination of these factors. Therefore, a systematic
| Reference | Measures | Stimulant description | N | Conclusion | Participants | Prevalence (lifetime if not otherwise indicated) |
|-----------|----------|-----------------------|---|------------|--------------|------------------------------------------------|
| 94        | Monitoring the Future survey | Adderall | N=21,137 | High-contact sports may influence male students to misuse stimulants as performance enhancers either on or off the playing field | Adolescents aged 13–17 years |         |
| 128       | Self-report ratings scales of substance use, stimulant use, and ADHD symptoms, Sensation Seeking Scale, Frost Multi-Dimensional Perfectionism Scale | Prescription stimulants | N=1,153 | Nonmedical and medical misusers had a higher prevalence of using and combining other substances, as well as greater reports of side effects compared with appropriate users | Undergraduates aged 18–25 years |         |
| 47        | Internal Restlessness Scale, Depression Anxiety Stress Scales-21, Stimulant Survey Questionnaire | Adderall, Ritalin | N=1,033 | Students who were members of fraternities and sororities reported higher rates of misuse compared with nonmembers | Undergraduates aged ≥ 18 years; fraternities and sorority members | 19.8% |
| 100       | Self-report rating scales of weight loss behaviors, motivations for weight loss, stress-related eating, self-esteem, and eating disorder symptoms | Adderall, Ritalin | N=705 | College students may be misusing stimulants for weight loss, which may be related to other problematic weight loss strategies | Undergraduates | 11.7% (misuse to lose weight) |
| 93        | National Survey on Drug Use and Health | Adderall, Ritalin, Dexedrine, MPH, dextroamphetamine | N=443,041 | Misuse of stimulants appears to be adopted by individuals already engaged in broader patterns of drug abuse and nonmedical use | Adolescents and adults aged ≥12 years | 3.4% |
| 117       | Stimulant Survey Questionnaire, Perceived Stress Scale, Sensation Seeking Scale, National College Health Assessment | Ritalin, Concerta, Metadate, Adderall, Dexedrine | N=165 | Students with ADHD reported higher rates of both prescription stimulant use and misuse compared with students without ADHD | Undergraduates aged ≥ 18 years; ADHD | 11.5% occasionally misuse; 1.4% frequently misuse |
| 44        | Brief Symptom Inventory, Internal Restlessness Scale, Sensation Seeking Scale, Stimulant Survey Questionnaire | Ritalin, Concerta, Metadate, Adderall, Dexedrine | N=390 | College students who reported misusing had higher levels of internal restlessness and psychological distress compared with those who did not report misuse. No significant difference was found between sex and stimulant misuse | Undergraduates aged ≥ 18 years | 7.5% (past month) |
| 89        | Structured face-to-face interview, self-report rating scale of ADHD symptoms | MPH | N=66 | Misuse of MPH was associated with other illicit substance use and diversion among a sample of adults with prescriptions for stimulant medication | Adults aged ≥ 18 years | 29% |

(Continued)
Table 3 (Continued)

| Reference | Measures | Stimulant description | N      | Conclusion                                                                 | Participants                  | Prevalence (lifetime if not otherwise indicated) |
|-----------|----------|-----------------------|--------|-----------------------------------------------------------------------------|-------------------------------|-------------------------------------------------|
| 102       | Drug Abuse Screening Test, self-report ratings of nonmedical use of prescription stimulants, past year other drug use, routes of administration | Ritalin, Dexedrine, Adderall, Concerta, MPH | N=3,639 | College students who reported misusing prescription stimulants were more likely to report using other substances compared with nonmisusers. Sex not significantly associated with misuse | Undergraduates | 8.5% (lifetime); 6.0% (past year) |
| 129       | National Survey on Drug Use and Health | Adderall, Ritalin, Dexedrine, Cylert, DextroStat, Concerta, MPH, dextroamphetamine | N=114,241 | Past-year prescription stimulant misuse was more prevalent among persons aged 12–25 years and among whites. Prevalence in large metropolitan areas was lower than, or similar to, that in less populated areas. About 13% of past-year stimulant misusers met the survey criteria for dependence or abuse | Adolescents and adults aged ≤12 years | 1.4% (past year) |
| 118       | Structured face-to-face interview | MPH | N=100 | College students who reported misusing MPH were more likely to report using other substances compared with nonmisusers | College students |                                                      |
| 92        | Self-report ratings of prescribed stimulant use, diversion of prescribed stimulants, illicit use of prescribed stimulants, heavy episodic drinking, monthly alcohol use, monthly cigarette use, annual marijuana use, annual ecstasy use | Ritalin, Dexedrine, Adderall | N=1,536 | Students who reported prescription stimulant misuse reported significantly higher rates of alcohol and other drug use. Prescription stimulant misuse was more prevalent among students with no plans for college | Adolescents aged 10–17 years | 4.5% |
| 84        | Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version, Structured Clinical Interview for DSM-IV self-report questionnaire about stimulant medication misuse and diversion | Stimulants | N=98 (ADHD n=55; no ADHD n=43) | Although the majority of participants with ADHD used their medications appropriately, these participants misused and diverted (11%) their prescription medications at higher rates than participants without ADHD in a sample of adults taking prescribed medications. All of the participants with ADHD who diverted their medication and 83% of those who misused their medications were comorbid for conduct disorder or substance use disorder. Immediate-release stimulants (MPH and mixed amphetamine salts) were the most common medications. Participants with ADHD reported misusing/diverting; however, extended release was not as prevalent in the included sample | Adolescents and adults; ADHD | 22% (participants with ADHD diagnosis) |
### Pharmacological Interventions for Adolescents and Adults with ADHD

| Page | Study Details | Participants | Findings/Notes |
|------|---------------|--------------|----------------|
| 130  | Pittsburgh Sleep Quality Index | N=492 | College students who reported nonmedical use of prescription stimulants reported worse subjective and overall sleep quality, as well as more sleep disturbance compared with nonusers. Undergraduates aged 18 years. |
| 111  | Questions about ADHD treatment and misuse and diversion of prescribed ADHD medication, side effects reported by PCPs, the Adult ADHD Self-Report Scale, and the Sheehan Disability Scale | N=115 | <1% of physicians suspected adults of diversion and 1.9% of adults reported diversion of stimulant medication. There was a high level of agreement between adult patients’ report and level of PCP distrust regarding use of taking a higher dose of ADHD drug than prescribed (79.7%) and use of ADHD drug combined with illegal substances (90.5%). Adults; ADHD. |
| 108  | Self-report questionnaire with mostly closed-ended, multiple-choice questions about student misuse of prescriptions drugs, motivation for nonmedical use, deceptive practices, frequency of use, consequences of nonmedical use, peer group nonmedical use, and an ethics-probing vignette | N=372 | The majority of misusers endorsed taking prescription stimulants to enhance alertness or energy (65.9%) or improve academic performance (56.7%). More than half (55.8%) of the students perceived stimulant misuse to be academically dishonest and more than half (59.9%) believed that it offers an unfair academic advantage. Medical, pharmacy, and respiratory therapy undergraduate and graduate students. |
| 119  | Student Life Survey; Adult Symptom Rating Scale; Cut Down, Annoyed, Guilty, eye-opener instrument; Drug Abuse Screening Test Short Form | N=1,738 | College students who reported misusing prescription stimulants were more likely to report cigarette smoking, binge drinking, and illicit use of cocaine. Undergraduates aged 18 years; past-year prescribed stimulant users. |
| 97   | Self-report survey that included questions about smoking status, illicit drug use, and misuse of prescription stimulant medications | N=545 | The most common specific medications were Adderall, Adderall XR, Ritalin. ADHD. Adolescents and adults aged 13 years; ADHD. |

(Continued)
| Reference | Measures                                                                 | Stimulant description | N  | Conclusion                                                                                                                                                                                                 | Participants                               | Prevalence (lifetime if not otherwise indicated) |
|-----------|--------------------------------------------------------------------------|-----------------------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-----------------------------------------------|
| 109       | Questionnaire of students’ experiences, perceptions of stimulant medication use at their institution, and use of stimulant medication for nonmedical reasons | Adderall, Ritalin, MPH | N=243 | 70% of dental and dental hygiene students reported nonmedical use of prescription stimulants to improve attention and/or concentration. The most commonly reported stimulant medication used nonmedically was Adderall (77%). 87% of the students obtained the medication through friends, and 90% began using the drug in college | Adults aged ≥ 18 years; dental and dental hygiene students | 12.4%                                         |
| 112       | Student Life Survey, self-report ratings of medically prescribed use of stimulant medication, illicit use of prescription stimulants, diversion of prescription stimulants, obtaining prescription stimulants, binge drinking, monthly alcohol use, annual marijuana use | Ritalin, Dexedrine, Adderall, Concerta | N=9,161 | Risk factors for illicit use of prescription stimulants include being male, white, a member of a social fraternity or sorority, Jewish religious affiliation, and having a lower GPA | Undergraduates aged ≥ 18 years | 8.1% and 5.4% (past year)                        |
| 57        | Adult ADHD Self-Report Scale, face-to-face interview, self-administered questionnaires | Adderall, Ritalin, Concerta | N=470 | ADHD symptoms, particularly inattention, were associated with being a nonmedical user of prescription stimulants | Undergraduates aged ≥ 18 years |                                              |
| 99        | Self-report questionnaire about nonmedical use of prescription stimulants and illicit use of stimulants | Methylphenidate, amphetamines | N=1,547 (1,035 pre and 512 university) | Males and students with poor grades reported higher lifetime prevalence rates than females and students with good grades among the preuniversity students. Friends and relatives were the main sources for prescription stimulants and the mean age for first time was 16.6 years and 23.3 years for preuniversity and university students, respectively | Preuniversity students aged 18–21 years, undergraduates aged 20–48 years | 1.29%, 0.26% (past year), and 0.06% (past month) |
| 49        | Center for Epidemiologic Studies Depression Scale, self-report ratings of nonmedical ADHD medication use, motivations for nonmedical ADHD medication use, perceived effects of nonmedical ADHD medication use, possible adverse consequences of nonmedical ADHD medication use, ADHD symptoms, nonmedical use of other medications, alcohol, tobacco, and drug use | ADHD medication | N=3,407 | The most frequently reported motive of nonmedical use of ADHD medication was to enhance the ability to study. Students perceived nonmedical use to be beneficial despite frequent reports of side effects | Undergraduates | 8.9% (since beginning college) and 5.6% (past 6 months) |

*Table 3 (Continued)*
| Page | Study Type | Population | Sample Size | Findings |
|------|------------|------------|-------------|----------|
| 48   | Stimulant Medication Use Questionnaire | Ritalin, Concerta, Metadate, Methyl, Dexedrine, Adderall, Desoxyn, Cylert | N=333 | Compared with non-illicit users, illicit users reported more motives to use, less concern with ethics and safety of use, and greater perception of use as socially acceptable. Undergraduates 20% |
| 103  | Question survey | Adderall, Adderall XR, Concerta, Stratera, Ritalin, Dexedrine | N=1,550 | College students who illicitly used prescription stimulants were more likely to use other drugs. College students aged ≥ 18 years 43% (participants without ADHD diagnosis) |
| 91   | National Survey of Drug Use and Health | Ritalin, Cylert, Adderall, Concerta | N=17,709 | Adolescents who utilize mental health treatment and engage in marijuana use and other illegal drugs have significantly increased risk for past-year nonmedical prescription stimulant use. Adolescents aged 12–17 years 1.7% (past year) |
| 113  | Student Life Survey, self-report ratings of medically prescribed use of stimulant medication, illicit use of prescription stimulants, diversion of prescription stimulants, obtaining prescription stimulants | Ritalin, Dexedrine, Adderall, Concerta | N=9,161 | The most frequently reported motives of illicit use of prescription stimulants were helping with concentration, increase alertness, and providing a high. Male students (9.3%) reported significantly higher lifetime rates than did females (7.2%). Lifetime rates were higher for white (9.5%) and Hispanic (8.9%) students than for African American (2.7%), Asian (4.9%), or other racial student groups (5.8%). Undergraduate aged ≥ 18 years 8.1% and 5.4% (past year) |
| 131  | ADHD Rating Scale, Massachusetts General Hospital Liking Scale | OROS-MPH | N=558 | In a sample of adolescents and adults with nicotine substance use disorder, adults rated OROS-MPH as more effective in treating ADHD, whereas adolescents reported feeling more depressed when taking OROS-MPH. Adolescents aged ≥ 18 years; substance abuse disorder; smokers |
| 110  | Stimulant Medication Use Questionnaire | Ritalin, Adderall, Cylert, Dexedrine, Concerta | N=1,025 | Motives of misuse or abuse of stimulant medication included improving attention, partying, and improving grades. Nearly all (96%) respondents who misused or abused and specified a stimulant indicated that Ritalin was their stimulant medication of choice, followed by Adderall (2%). Undergraduate and graduate aged ≥ 17 years, ADHD 16.2% |
| 96   | Adolescent Drug and Alcohol Diagnosis | Adderall, Dexedrine, MPH, dextroamphetamine | N=450 | Of adolescents in a substance abuse treatment center who reported nonmedically using MPH or dextroamphetamine, 88% reported nonmedical use of MPH. Abusers were less likely to be attending school and increased likelihood of having a concurrent eating disorder. Adolescents aged 12–18 years; substance abuse disorder 2.3% |

(Continued)
| Reference | Measures | Stimulant description | N | Conclusion | Participants | Prevalence (lifetime if not otherwise indicated) |
|-----------|----------|-----------------------|---|------------|--------------|-----------------------------------------------|
| 52        | Recreational Stimulant Use Survey | MPH, amphetamine salts | N=448 | No statistically significant differences were found for sex or ethnicity in prevalence of stimulant misuse. 8% of students reported selling or giving away their prescription medication, 63% reported knowing someone who diverted their medication, and 67% reported knowing someone who had taken medication recreationally | Undergraduates aged ≥ 18 years | 18% |
| 95        | Structured face-to-face interview | MPH, dextroamphetamine | N=162 | In a sample of adolescents in an addiction treatment setting, patients with a diagnosis of ADHD more likely to have a lifetime history of stimulant abuse than those with no ADHD diagnosis | Adolescents aged 13–20 years; substance abuse disorder; ADHD | |
| 105       | Self-report questionnaire including demographic questions, MPH information-related questions, questions about frequency of MPH use, and questions about perceptions of MPH rise in use | MPH | N=310 | Iranian medical students reported relatively low levels of knowledge about MPH; however, increased time at university was associated with increased knowledge of MPH. Men demonstrated higher rates of MPH use than women and medical students with lower GPA were more likely to use MPH illegally than those with higher GPAs. Increased concentration was cited as the most common reason for MPH use | Adults aged 18–28 years; medical students | 8.7%, 6.5% (past year), and 1% (past month) |
| 104       | Prescription Stimulant Expectancy Questionnaire, Sensation Seeking Scale, self-report rating scale of symptoms of ADHD | Adderall, Ritalin | N=42 | Among a sample of students with prescriptions for stimulants, of those who reported misusing, 62.8% reported taking a higher dose than prescribed. Compared with nonmisusers, misusers of prescription stimulants were more likely to use a greater number of illicit substances, and reported higher hyperactivity symptoms and sensation seeking | Undergraduate; ADHD | 45.2% |
| 54        | Question survey, face-to-face interview | Adderall | N=1,811 | Most illegal users reported using ADHD stimulants primarily in periods of high academic stress and found them to reduce fatigue while increasing cognition and memory | College students | 34% (participants with no prescription for ADHD medication) |
| 56        | Face-to-face interview | Prescription stimulants | N=1,253 | Among students across 4 years of college, frequency of past-year nonmedical use of prescription stimulants was stable over time, averaging 11.3 days (SD =15.3) in year 2, 12.1 days (SD =20.8) in year 3, 13.3% at year 1 and 31% by year 4 | College students aged 17–19 years | 31% by year 4 |
| Page | Methodology | Stimulants | Participants | Findings |
|------|-------------|------------|--------------|----------|
| 88   | Computer-assisted personal interview, audio computer-assisted self-interview | Adderall, Ritalin, MPH | N=68,736 | Adults (aged 26–34 years) and whites reported having misused stimulants more than other age and racial groups. Ritalin and other methylphenidates were misused at higher rates than Adderall |
| 116  | Self-report questionnaire, UPPS-P | Prescription stimulants | N=206 | Nonmedical use of prescription stimulants was associated with increases in lack of premeditation, sensation seeking, positive expectancies, and positive evaluations |
| 106  | Question survey of ADHD diagnosis, treatment history and nonmedical use of prescription stimulants | Methylphenidate, amphetamine salts | N=388 | Medical students appear to be a relatively high-risk population for nonmedical prescription stimulant use |
| 58   | Patient Health Questionnaire, self-report ratings of nonmedical use of prescription stimulants, routes of administration | Ritalin, Dexedrine, Adderall, Concerta, MPH | N=3,639 | Of the participants who reported nonmedical use of prescription stimulants, 39.2% used on 1–2 occasions, 31.6% used on 3–5 occasions, 11.3% used on 6–9 occasions, and 17.9% used on ≥10 occasions. Respondents who misuse frequently (51.4%) or nonorally (47.7%) had the highest rates of depressed mood in the past month |
| 90   | Question survey | Adderall, Ritalin, Dexedrine, MPH, dextroamphetamine, mixed-salts amphetamines | N=307 | Fraternity members who reported nonmedical use of prescription stimulants were significantly higher among upper classmen, those living off-campus, and those who regularly smoked marijuana |
| 114  | National Survey on Drug Use and Health | Ritalin, MPH | N=23,645 | Nonmedical prescription stimulant use was associated with psychological distress, sensation seeking, binge drinking, and college enrolment |
| 98   | Standard self-report measures of substance use | Adderall, Concerta, Ritalin, Dexedrine | N=4,572 | White students (11.3%) reported significantly higher rates of lifetime stimulant misuse than African American (3.0%) or Hispanic (5.6%) students. The odds of substance use behaviors were greater among nonmedical stimulant users compared with medical users or individuals who indicated never using stimulant medication |
Table 3 (Continued)

| Reference | Measures                                                                 | Stimulant description         | N                  | Conclusion                                                                                                           | Participants               | Prevalence (lifetime if not otherwise indicated) |
|-----------|---------------------------------------------------------------------------|--------------------------------|--------------------|---------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------------------|
| 115       | Self-report survey addressing stress, wellness, and coping, questions about psychostimulant use, and wastewater samples collected for 72-hour periods at 1-hour intervals at three time points from four residence halls comprising 476 undergraduate students | Adderall, Ritalin, or other ADHD medication | N=627; 468; 400 (first week of classes, midterms, finals, respectively) | Self-report of psychostimulant use and psychostimulant use measured via campus wastewater samples were significantly increased during periods of stress (midterms) compared with the first week of school | Undergraduate students     | 11.7% (Adderall), 8.5% (Ritalin), 5% (both) |
| 107       | Web-based survey about cognitive enhancement drug use                      | Amphetamines, other psychostimulants | N=1,115            | 11% of students reported using prescription psychostimulants during medical school. First experiences were most commonly reported in college (57%) and in medical school (22%). Psychostimulant use was associated with being male and other drug use. Although half of the sample perceived using psychostimulants for academic performance enhancement to be a problem, 21% did not perceive it to be a problem. The majority (95%) of students reporting using psychostimulants believed that academic standing could be improved by taking psychostimulants | Adults aged 20–49 years; medical students | 18% |
| 53        | Web-based survey                                                           | Ritalin, Concerta, Metadate, MPH | N=2,087            | College students reported using MPH nonmedically for recreational reasons as well as to improve academic performance. 53% of the nonmedical users were male. Nearly 74% of nonmedical users were white | College students aged 18–24 years | 5.3% |
| 87        | Web-based survey                                                           | Prescription stimulants, ADHD medications | N=4,297            | Of participants aged 18–25 years, 4.3% reported nonmedical use of ADHD medication compared with 1.3% among those aged 26–49 years. Friends and family members were the most reported source of ADHD medication for respondents who did not have a prescription. The most frequently reported motive of illicit use of prescription stimulants was productivity (40%), followed by staying awake (23%) | Adults aged 18–49 years | 7.1% and 2% (past year) |

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; GPA, grade point average; LA, long acting; MPH, methylphenidate; OROS, osmotic release oral system; PCP, primary care physician; SD, standard deviation; UPPS-P, urgency, premeditation, perseverance, sensation seeking, and positive urgency; XR, extended release.
assessment and inclusion of effect sizes was beyond the scope of the present article.

The studies reviewed indicate that prescription stimulant misuse is a growing problem across adolescent and adult populations. Estimates of lifetime prevalence range from 7.1% to 29% among adults, 5.3% to 55% among college students, and 1.7% to 4.5% among adolescents. Although estimates of stimulant misuse prevalence appear to be relatively low among general adolescent samples, estimates of stimulant misuse among adolescents using other substances (23%–31%) and among adolescents and adults receiving treatment for ADHD (14%) are much higher. Estimates of lifetime stimulant misuse also appear to increase as adolescents reach higher grade levels. For example, among high school seniors, McCabe and West reported that nearly 10% admitted to using prescription stimulants nonmedically at least once. Similarly, lifetime prevalence estimates in college have been shown to grow as students reach their final years of school. Garnier-Dykstra et al reported that although only 13.3% of first year students reported stimulant misuse, by their fourth year 31% reported misuse.

In addition to college level, lifetime estimates of stimulant misuse may vary according to several other variables. For example, prevalence of stimulant misuse specifically for cognitive enhancement was estimated to be <2% in a sample of preuniversity (students preparing to attend university) and university students in Germany, but prevalence estimates of stimulant misuse for the purpose of weight loss has been reported to be nearly 12%. Studies assessing stimulant misuse among general samples of college students have reported rates between approximately 8% and 34%. Much higher estimates of stimulant misuse have been reported among samples of college students with ADHD (43%) or with prescriptions for stimulant medication (45.2%). The highest estimates of prevalence of stimulant misuse among college students (55%), however, have been reported among a sample of fraternity members.

Among medical students, lifetime prevalence estimates for engaging in prescription stimulant misuse have ranged between 9%–10% and 18%. Moderate lifetime prevalence estimates of stimulant misuse have also been reported among undergraduate and graduate health care students (11%), dental and dental hygiene students (12.4%), and general samples including both undergraduate and graduate students (16.2%–17.5%).

Compared with adolescents and college students, very few studies have addressed prevalence estimates of stimulant misuse among adults aged ≥18 years outside of the university setting. Novak et al reported that 2% of the 4,297 adults sampled indicated that they had engaged in nonmedical use of ADHD medications in the past year and 7.1% in their lifetime. Pilkinton and Cannatella reported similar rates (7.1%) for lifetime prevalence estimates among a sample of both adolescents and adults. However, estimates of stimulant misuse prevalence among adults with prescriptions for stimulant medications have yielded much higher rates (29%), similar to adolescent populations. Finally, Lensing et al explored physician and adult patient agreement regarding prescription stimulant misuse and diversion and found that <1% of physicians suspected their patients of diversion and <2% of the adults themselves reported diversion of prescription stimulants, yielding a high level of agreement between the two.

Studies examining characteristics of students engaging in stimulant misuse have yielded relatively consistent findings regarding sex and race/ethnicity. Although multiple studies reported that male students have indicated higher rates of lifetime stimulant misuse than female students in university settings, several studies have also failed to find differences between males and females among college students and high school senior students. These conflicting findings may be due to differences in measurement. For example, although Franke et al reported sex differences in lifetime prevalence of stimulant misuse for cognitive enhancement, the researchers did not find differences across males and females in past year or past month stimulant misuse. On the other hand, the vast majority of studies examining racial and ethnic differences related to stimulant misuse have reported that young adults, college students, and adults who are white are more likely to misuse stimulants than students of other races and ethnicities. Only one study reported that there were no differences in ethnicity regarding prevalence of stimulant misuse; however, <12% (n=37) of the study’s sample included students of color, limiting statistical power and thus conclusions regarding differences in prevalence among ethnic differences.

Interestingly, studies examining characteristics of adolescents who partake in nonmedical stimulant use indicate that students without plans to attend college have been shown to report a higher prevalence of stimulant misuse than those who plan to attend college, and adolescents who report prescription stimulant misuse may be less likely to attend school. However, college students appear to be particularly vulnerable to stimulant misuse, and members of fraternities and sororities have reported higher rates of misuse than students unaffiliated with Greek organizations.
One of the reviewed studies found that college students who are upper classmen or live off-campus may be more likely to engage in nonmedical stimulant use. Additional correlates of stimulant misuse among college students have included affiliation with a Jewish religion, perceiving stimulant use as normative, and engaging in problematic weight loss strategies. Weight loss, however, may not be unique to college students, as adolescent prescription stimulant misusers have been found to be more likely to have an eating disorder than students who did not misuse stimulants. Finally, all types of students (adolescents, adults, and medical) performing worse academically appear to be more likely to engage in nonmedical prescription stimulant use. Indeed, this review found that the most commonly reported reasons university students take prescription stimulants are related to academics, and studies suggest that during periods of high academic stress, college students may be more likely to use prescription stimulants, as indicated by self-report measures and by measurements of stimulant levels in campus wastewater samples.

It is not surprising, then, that procrastination and difficulty with time management have also been shown to relate to stimulant misuse among college students. Further, stimulant misuse among college students has been shown to relate to higher levels of hyperactivity, sensation seeking, depression, internal restlessness, and psychological distress and lower levels of premeditation. ADHD diagnoses and symptoms may also relate to stimulant misuse. Adolescents, college students, and adults diagnosed with ADHD have reported higher levels of prescription stimulant misuse than students without ADHD, and ADHD symptoms have been shown to correlate with nonmedical use of prescription stimulants. It is important to note, however, that studies suggest that the vast majority of individuals with ADHD do not misuse or divert their stimulant medications.

The studies included in the present review also indicate that in addition to ADHD, diagnoses of conduct disorder and SUD are associated with increased nonmedical prescription stimulant use and diversion in adolescents and adults. Illicit drug use among adolescent and university students is also associated with misuse of prescription stimulants. Several studies in the current review assessed student perspectives on prescription stimulant misuse, and findings revealed that students’ opinions on the ethical implications of taking illicit prescription stimulant medications to enhance academic outcomes are mixed. For example, Bossaer et al reported that health care students were split between considering stimulant misuse to be academically dishonest and proffering unfair academic advantages. Similarly, half of the medical students sampled by Emanuel et al perceived stimulant misuse to be a problem, but 20% did not. Students who report engaging in stimulant misuse, however, may feel less conflicted regarding ethical implications. For example, Judson and Langdon reported that compared with nonillicit users, illicit users demonstrated fewer concerns regarding the safety and ethics of using stimulant medication.

Whether or not students consider their decision to engage in stimulant misuse to be ethical, students misusing stimulants appear to expect positive outcomes. Indeed, students who have reported taking stimulant medications illicitly have endorsed feeling a reduction in fatigue and improvement in cognition and memory after taking prescription stimulants. The present findings also indicate that students who misuse tend to perceive the benefits as outweighing the risks, despite the fact that little is known about the physiological and cognitive effects of prescription stimulant medications among populations without ADHD. Two of the reviewed studies suggest that individuals misusing stimulants may be more likely to take short-acting agents than long-acting agents. Wilens et al and Bright, for example, reported that adolescents and adults were more likely to misuse short-acting agents than long-acting agents, suggesting that immediate-release agents have more potential for abuse. Results were mixed regarding the most commonly misused fast-acting stimulant, with Ritalin (MPH) more likely to be misused than Adderall among adults, but nearly 12% of college students reported misusing Adderall compared with 8.5% misusing Ritalin.

## Discussion

### Effectiveness of ADHD treatment options

Studies included in this review revealed that the medical use of prescription stimulants is efficacious in reducing ADHD symptoms and may improve cognitive and psychosocial outcomes in individuals diagnosed with ADHD. Specifically, research investigating LDX in comparison with placebo consistently found LDX efficacious across 30, 50, and 70 mg/day. Two studies, however, found that higher doses related to greater improvements in overall functioning. Most notably, the present findings support that LDX is effective for reducing ADHD symptomatology across different ages. Among adults with ADHD, LDX was also found to positively affect executive functions, quality of life, and performance productivity. Additionally, LDX has been found to be effective in reducing ADHD symptoms with individuals with comorbid depression and SUD. Although these results are encouraging, it is important to note that most
studies did report negative side effects from LDX, such as decreased appetite, weight loss, and nasal congestion. More severe side effects, however, including tachycardia, increased blood pressure/hypertension, and anxiety, were reported by <5% of the included study samples, and no individuals died while participating in these studies.

Similar to those investigating LDX, studies examining the efficacy of MPH and D-AMP consistently found such treatment options to be associated with fewer ADHD symptoms compared with placebo. These positive effects were found among long-acting and short-acting stimulant medications, and one study reported similar effects for both males and females. Although higher doses generally proved to be more effective at reducing ADHD symptoms, low to moderate doses of stimulants may also be effective at reducing ADHD symptomatology.

Such treatment options examined in this review were associated with enhanced cognitive performance, executive functioning, and quality of life and fewer emotional symptoms. Although MPH and D-AMP have proved to be efficacious in treating ADHD symptomatology, it is important to consider their side effects that are similar to LDX: decreased appetite, weight loss, headache, insomnia, abdominal pain, dizziness, nervousness, emotional lability, and dry mouth. Although rare, more severe side effects of these medications have included psychosis, seizures, and cardiac events such as tachycardia, hypertension, myocardial infarction, and sudden death.

Overall, however, these results are consistent with the child literature indicating that stimulant and stimulant medications, when used as prescribed, are a safe and efficacious treatment option for improving attention and decreasing hyperactivity and impulsivity symptoms. What remains less clear, however, is whether these medications affect academic and work-related outcomes of adolescents and adults without ADHD. Although one study reported improvements in measured cognition from MPH and another found that students who misuse stimulant medication perceive positive academic effects, none of the studies included in the present review examined changes in quality of work or student grade or productivity after taking stimulant medications. Given that cognitive enhancement-related reasons are considered the primary motivation for college students misusing prescription stimulant medications, future research examining the effects of prescription stimulants on direct measures of academic success (eg, studying and concentration, grade performance, quality of writing, and reading comprehension) is warranted.

An additional area that warrants attention concerns the efficacy of nonstimulant medication for the reduction of ADHD symptoms and any potential effects for cognitive enhancement. The present review was unable to identify any studies examining nonstimulant efficacy among adults and adolescents meeting the required eligibility criteria. Given the lower abuse potential associated with nonstimulant medication, use of these medications among populations more susceptible to diversion and misuse may be prudent. Such a recommendation, however, is contingent on a demonstration of the efficacy of nonstimulants among adolescent and adult populations most at risk for stimulant abuse.

Finally, although prescription stimulant medication is considered the front line of pharmacotherapy for ADHD treatment in adolescents and adults, these drugs have significant diversion and misuse potential. In fact, the present review revealed that the medical use of prescription stimulants is associated with increased stimulant misuse among students with ADHD, with one study reporting misuse rates of 62.8% among participants with a valid prescription.

**Stimulant misuse**

Results from the present review indicate that a significant percentage of adolescents and adults are engaging in nonmedical stimulant misuse, which is consistent with previous research examining college students specifically. Results revealed lifetime prevalence rates of stimulant misuse ranging from 1.7% to 55%, with reports varying across the population being examined. A limitation of this body of literature is the dearth of studies investigating the prevalence of prescription stimulant misuse among college students outside of the US, which impedes cross-cultural comparisons regarding prescription stimulant misuse.

Similar to previous studies examining the nonmedical use of stimulants, the present review revealed that estimates vary according to numerous variables. For example, one trend that has emerged is that as individuals reach higher grade levels, they misuse at greater rates. Although increased exposure to prescription stimulants may be one reason students report higher prevalence rates of stimulants as they increase in age, these findings suggest that prescription stimulants may also be misused more frequently as coursework becomes more challenging and academic success becomes more difficult to obtain. Indeed, as indicated in this review, academic performance has been reported as the primary motive for this behavior. A critical finding, however, is that prescription stimulant misuse has been found to be negatively associated with academic performance. For example, Arria et al reported that college freshmen who used prescription stimulants nonmedically had poorer study skills (eg, skipped classes more often and spent less time studying and more time socializing) and poorer academic performance (GPA) in high school and college than students who did not endorse stimulant misuse.
Despite the negative relationship between academic performance and stimulant misuse, most students who endorse the nonmedical use of stimulants perceive them as effective and helpful for enhancing their academic performance. For example, Weyandt et al found that >20% of students in their sample agreed or strongly agreed that the occasional nonmedical use of prescription stimulants is harmless. Additionally, stimulant misusers may be less concerned about the safety and ethical implications of stimulant misuse compared with students who do not misuse stimulants. Findings suggest, however, that general student populations are conflicted about the ethical implications of stimulant misuse.

Although individuals without ADHD have endorsed positive effects from misusing stimulant medication, to date only one study has explored the effects of Adderall on college students without ADHD, and this study, in general, did not find enhancement of cognitive abilities, despite the students’ impression that it was improving their performance. Similar performance-enhancing impressions have been made of MPH, and have led to the popularity of its use among adolescents and college students with and without ADHD. In addition, the present review suggests that adolescents and adults are more likely to misuse short-acting or immediate-release agents compared with long-acting agents. Consistent with previous studies, the present review suggests that students who are white, affiliated with a fraternity or sorority, engaging in other illicit drugs, and male, are more likely to misuse prescription stimulants.

Although some of the studies reported no sex differences, recently Weyandt et al reported on the effect sizes of sex differences in studies examining stimulant misuse. Cohen’s d effects ranged from 0.88 to 5.38, suggesting that males are misusing at greater rates than females.

Implications
Pharmacotherapy is the principal choice of treatment for ADHD among children, adolescents, college students, and adults. Because stimulants are the most frequently prescribed drug for college students with ADHD, and most college students with ADHD take prescription stimulants, more double-blind, placebo-controlled studies examining the effectiveness of these medications in college students are warranted. It is important to note, however, that there is recent evidence that prostimulants may also be effective at improving symptoms in individuals with ADHD.

The present review provides evidence that college students with ADHD and those with a stimulant prescription are taking part in greater levels of stimulant misuse compared with those without the disorder. Although individuals with ADHD may greatly benefit from stimulant medication, these prescription medications have significant abuse potential when they are not used as prescribed. All prescription stimulants that are used to treat ADHD are controlled substances; however, abuse liability varies based on the delivery system in which the medication activates. For example, Svetlov et al reported that although MPH and AMPH have similar psychopharmacological effects, they do have different neurochemical mechanisms of action. Such differences are essential to consider, as MPH appears to have less rewarding abilities, lowering its chances of dependence, especially when taken as prescribed. A second example includes the requirement of enzymatic hydrolysis for LDX before its therapeutic effects are achieved, which results in a slow increase of D-AMP levels, potentially lowering its use for diversion or misuse. Indeed, recent research has examined the effects of LDX in a group of stimulant abusers who did not have ADHD, and found that intravenous doses of LDX had greater abuse-related disliking compared with placebo. Specifically, Jasinski and Krishnan administered 100 mg of LDX and 40 mg of D-AMP to individuals, also reporting that intravenous doses of D-AMP have significantly more abuse-related liking effects compared with placebo. Additionally, because of its chemical properties, LDX cannot be ground or dissolved into a short-acting stimulant, which has been the stimulant of choice for stimulant misusers. Given the demonstrated effects of LDX on improving ADHD symptomology, as well as executive function, and its demonstrated greater abuse-related disliking, LDX may be the ADHD medication of choice for college students with ADHD who are at risk for stimulant misuse. LDX may also be a good choice for prescribers working with the college student population to help prevent stimulant diversion among valid prescription holders and misuse among college students without ADHD. Results of this review also suggest that health care providers should inform their patients of the health and legal risks associated with the misuse of prescription medications, and monitor the use of these medications on a frequent basis. Lastly, health care providers involved in prescribing ADHD-related medications should be thoroughly trained in the proper assessment, diagnosis, and treatment of ADHD to ensure diagnostic accuracy and treatment effectiveness.

In addition to educating prescribers about the rates of misuse and diversion, as well as the variables associated with stimulant misuse, it is critical that prevention and intervention efforts be made amongst health care providers and educators.
at the middle school, high school, and higher education levels. Further efforts should target particularly higher-risk college populations such as fraternities and sororities. Information regarding the potential side effects of stimulant medications taken at varying doses and by different methods (eg, snorting or injecting), in addition to side effects resulting from the ingestion of medication as prescribed, should be made available to students in particular. Students should also be informed of the dangers of coingestion of prescription stimulants with other substances (eg, alcohol and cocaine), and particular emphasis should be placed on maintaining security of their medication (eg, lockboxes). Students who are misusing prescription stimulants without medical guidance are placing themselves at health and psychological risk, in addition to legal consequences for buying, selling, and diverting their medications.120

The inclusion of a psychoeducational component that focuses on inaccurate perceptions of safety surrounding nonmedical prescription stimulant use would be beneficial to intervention as well. Students who are at risk for stimulant misuse with academic problems can be provided with various support, such as tutoring and structured environments for studying and work completion. This additional support may encourage a school culture of clear expectations, educational support, and effective study habits, rather than competitiveness. For individuals who have been misusing stimulants or are inclined to misuse, it is imperative to discuss the motivating factors and determine any possibly undiscovered psychological, social, and/or emotional problems related to misuse or the desire to misuse. By pinpointing and addressing the core cause of stimulant use, students can be provided with the resources that will directly provide them with benefits and alternative methods to meet their specific needs. Thus, students should be educated about the potential side effects and risks associated with prescription stimulant misuse, as well as encouraged to access campus resources for academic and psychological support.45,47

Conclusion
Results from the present review support that both stimulant and prostimulant medications (including LDX, MPH, AMPH, and MAS), when used as prescribed, are safe and effective options for reducing ADHD symptoms in adolescents and adults with ADHD. Preliminary studies also suggest that prescription stimulants may improve psychosocial outcomes (eg, quality of life, self-concept, and obsessive–compulsive symptoms) for those with ADHD. Research explicitly examining effects of prescription stimulants on academic and cognitive functioning in students without ADHD is sorely limited, yet the current review revealed that alarmingly high percentages of adolescents and adults are engaging in nonmedical prescription stimulant use primarily for cognitive enhancement. Results of the present review also revealed a higher rate of prescription stimulant misuse among individuals with ADHD compared with individuals without the disorder, and that short-acting agents are more likely to be misused than long-acting agents. These findings emphasize the need for additional research concerning the misuse of prescription stimulants and have direct implications for prevention and intervention efforts to reduce prescription stimulant misuse among adolescents and young adults.

Acknowledgment
Research reported in this publication was supported by the National Center for Research Resources of the National Institutes of Health under Award Number G20RR030883. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosure
The authors report no conflicts of interest in this work.

References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
2. Barkley RA, Murphy KR, Fischer, M. ADHD in Adults: What the Science Says. New York, NY: Guilford; 2008.
3. Resnick RJ. Attention deficit hyperactivity disorder in teens and adults: they don’t all outgrow it. J Clin Psychol. 2005;61(5):529–533.
4. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey replication. Am J Psychiatry. 2006;163(4):716–723.
5. Faraone SV, Biederman J, Lehman BK, et al. Intellectual performance and school failure in children with attention deficit hyperactivity disorder and in their siblings. J Abnorm Child Psychol. 1993;102(4):616–623.
6. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York: Guilford; 2006.
7. Danforth JS, Connor DE, Doerfler LA. The development of comorbidity conduct problems in children with ADHD: an example of an integrative developmental psychopathology perspective. J Atten Disord. Epub January 10, 2014.
8. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: an 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1990;29(4):546–557.
9. Molina BS, Hinshaw SP, Swanson JM, et al; for the MTA Cooperative Group. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484–500.
10. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2006;157(5):816–818.
11. Weyandt LL, Iwaszuk W, Fulton K, et al. The Internal Restlessness Scale: performance of college students with and without ADHD. J Learn Disabil. 2003;36(4):382–389.

12. Sibley MH, Kuriyan AB, Evans SW, Waxmonsky JG, Smith BH. Pharmacological and psychosocial treatments for adolescents with ADHD: an updated systematic review of the literature. Clin Psychol Rev. 2014;34(3):218–232.

13. Weyandt LL, DuPaul GJ. College Students with ADHD: Current Status and Future Directions. New York, Springer: 2013.

14. Americans With Disabilities Act 1991, Pub L No 101–336, 26 July 1990, 104 Stat 328 (1991). Available from http://www.ada.gov/pubs/adastatute08.htm. Accessed July 25, 2014.

15. Wolf LE, Simkowitz P, Carlson H. College students with attention-deficit/ hyperactivity disorder. Curr Psychiatry Rep. 2009;11(5):415–421.

16. Weyandt LL, Linterman I, Rice JA. Reported prevalence of attention difficulties in a general sample of college students. J Psychopathol Behav Assess. 1995;17(3):293–304.

17. Garnier-Dykstra LM, Pinchesky GM, Caldeira KM, Vincent KB. Adult ADHD.

18. Heiligenstein E, Conyers LM, Berns AR, Miller MA. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. J Amer Coll Health Assoc. 2010;59(2):133–136.

19. Heiligenstein E, Conyers LM, Berns AR, Miller MA. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. J Amer Coll Health Assoc. 1998;46(4):185–188.

20. Beverstock AC, Finlay F. Who manages the care of students with attention deficit hyperactivity disorder (ADHD) in higher education? Child Care Health Dev. 2003;29(3):163–166.

21. Spencer TJ, Biederman J, Wilens T. Pharmacotherapy of ADHD with antidepressants. In: Barkley R, editors. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd ed. New York, Guilford Press; 1998:552–563.

22. Br J Addict. 2004;99(3):643–656.

23. Canu WH, Carlson CL. Rejection sensitivity and social outcomes of young adult men with ADHD. J Atten Disord. 2007;10(3):261–275.

24. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartwelder HS. Adjustment to measuring ADHD symptomatology in college students. J Atten Disord. 2008;11(6):677–688.

25. Norwalk K, Norvilitis JM, MacLean MG. ADHD symptomatology and its relationship to factors associated with college adjustment. J Atten Disord. 2009;13(3):251–258.

26. Shaw-Zirt B, Popali-Lehane L, Chaplin W, Bergman A. Adjustment, social skills, and self-esteem in college students with ADHD. J Amer Coll Health Assoc. 2005;53(3):109–120.

27. Reiser A, Prevat F, Petcher Y, Proctor B. The learning and study performance of a sample of adults with ADHD, developmental reading disorder, and ADHD. J Atten Disord. 2009;12(5):449–459.

28. Adler LA, Spencer T, McGough JJ, Jiang H, Huang HC, Yang LK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2013;16(9):1959–1973.

29. Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R. Long-term effectiveness and safety of dexmethylphenidate extended release capsules in adult ADHD. J Atten Disord. 2009;12(5):449–459.

30. Dupaul GJ, Weyandt LL, Rossi, JS, et al. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adult ADHD. J Atten Disord. 2012;16(3):202–220.

31. Ni HC, Chang CY, Gau SS, Lin YJ, Huang HC, Yang LK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2013;16(9):1959–1973.

32. Dupaul GJ, Weyandt LL, O’Dell, SM, Varejao M. College students with ADHD: current status and future directions. J Atten Disord. 2009;13(3):234–250.

33. Heiligenstein E, Guenther G, Hsu K, Herman K. Depression and academic impairment in college students. J Amer Coll Health Assoc. 1996;45(2):59–64.

34. Huss M, Ginsberg Y, Tvedten T, et al. Methylphenidate hydrochloride modified release provided improved inattention and hyperactivity/impulsivity scores in adult ADHD patients. Eur Neuropsychopharmacol. 2013;23(2):604–605.

35. Staufier WB, Greydanus DE. Attention-deficit/hyperactivity disorder psychopharmacology for college students. Pediatr Clin North Amer. 2005;52(1):71–84.

36. Weyandt LL, DuPaul GJ. ADHD in college students: a review of the literature. J Atten Disord. 2006;10(1):9–19.

37. Collins SH. Abuse liability of medications used to treat attention-deficit/ hyperactivity disorder (ADHD). Amer J Addict. 2007;16(1):35–44.

38. Weyandt LL, Janusis G, Wilson KG, et al. Nonmedication prescription stimulant use among a sample of college students: relationship with psychological variables. J Atten Disord. 2009;13(3):284–296.

39. Weyandt LL, Marraccini ME, Gudmundsdottir BG, et al. Misuse of prescription stimulants among college students: a review of the literature and implications for morphological and cognitive effects on brain functioning. Exp Clin Psychopharmacol. 2013;21(5):385–407.

40. Babcock Q, Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. J Amer Coll Health Assoc. 2009;49(3):143–145.

41. Dussault C, Weyandt LL. An examination of prescription stimulant misuse and psychological variables among sorority and fraternity college populations. J Atten Disord. 2013;17(2):87–97.

42. Judson R, Langdon SW. Illicit use of prescription stimulants among college students: prescription status, motives, theory of planned behaviour, knowledge and self-diagnostic tendencies. Health Psychol Behav Med. 2009;14(1):97–104.

43. Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartwelder HS. Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems? J Atten Disord. 2009;13(3):259–270.

44. Verdi G, Weyandt LL, Zavras BM. Non-medical prescription stimulant use in graduate students: relationship with academic self-efficacy and psychological variables. J Atten Disord. Epub April 22, 2014.

45. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Br J Addict. 2005;99(1):96–106.

46. Sharp JT, Rosén, LA. Recreational stimulant use among college students. J Subst Use. 2007;12(2):71–82.

47. Dupont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict. 2008;17(3):167–171.
54. DeSantis AD, Webb EM, Noar SM. Illicit use of prescription ADHD medications on a college campus: a multimethodological approach. J Am Coll Health Assoc. 2008;57(3):315–324.

55. US Food and Drug Administration. FDA Directs ADHD Drug Manufacturers to Notify Patients About Cardiovascular Adverse Events and Psychiatric Adverse Events; 2007. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007;ucm108849.htm. Accessed June 25, 2014.

56. Garnier-Dykstra LM, Caldeira KM, Vincent KB, O’Grady KE, Arria AM. Nonmedical use of prescription stimulants during college: four-year trends in exposure opportunity, use, motives, and sources. J Am Coll Health Assoc. 2012;60(3):226–234.

57. Arria AM, Garnier-Dykstra LM, Caldeira KM, Vincent KB, O’Grady KE, Wish ED. Persistent nonmedical use of prescription stimulants among college students: possible association with ADHD symptoms. J Adolesc. 2011;15(5):347–356.

58. Teter CJ, Falone AE, Cranford JA, Boyd CJ, McCabe SE. Non-medical use of prescription stimulants and depressed mood among college students: frequency and routes of administration. J Subst Abuse Treat. 2010;38(3):292–298.

59. Okoli C, Schabram K. A guide to conducting a systematic literature review of information systems research. Sprouts: Working Papers on Information Systems. 2010;19(26):1–49.

60. Cohen JA. A power primer. Psychol Bull. 1992;112:155–159.

61. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373.

62. Faroane SV, Spencer TJ, Kollins SH, Glatt SJ, Goodman D. Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study. J Adolesc. 2012;16(2):118–127.

63. Kollins SH, Youcha S, Lasser R, Thase ME. Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. Innov Clin Neurosci. 2011;8(2):28–32.

64. Wigal SB, Wigal T, Schuck S, et al. Academic, behavioral, and cognitive effects of OROS methylphenidate on older children with attention deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(2):121–131.

65. Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(4):395–405.

66. Brams M, Giblin J, Gasior M, Gao J, Wigal T. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. Postgrad Med. 2011;123(3):99–108.

67. Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977–983.

68. Ayag N, Yechiam E, Carmel Z, Levkovitz Y. Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. Psychopharmacology (Berl). 2010;210(4):511–519.

69. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68(2):268–277.

70. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed doses of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981–989.

71. Reitz W, Rösler M, Ose C, et al. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. World J Biol Psychiatry. 2012;13(1):48–59.

72. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456–463.

73. Spencer T, Wilens T, Biederman J, Weisler R, Read S, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266–279.

74. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Prestreich L. Efficacy and safety of dexamphetamine extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380–1387.

75. Stein MA, Waldman ID, Charney E, et al. Dose effects and comparative effectiveness of extended release dexamphetamine and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21(6):581–588.

76. Rösler M, Fischer R, Ammer R, Ose C, Reitz W A randomized, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120–129.

77. Rösler M, Reitz W, Fischer R, et al. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry. 2010;11(5):709–718.

78. Mikami AY, Cox DJ, Davis MT, Wilson HK, Merkel RL, Burket R. Sex differences in effectiveness of extended-release stimulant medication among adolescents with attention-deficit/hyperactivity disorder. J Clin Psychol Med Settings. 2009;16(3):233–242.

79. Bouttard R, Hechtman L, Minde K, Iaboni-Kassab F. The efficacy of 2 different doses of methylphenidate in treating adults with attention-deficit-hyperactivity disorder. Can J Psychiatry. 2003;48(8):546–554.

80. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buiteraak JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder: a randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004;34(6):973–982.

81. Spencer TJ, Adler LA, Weisler RH, Youcha, SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69(9):1437–1448.

82. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–639.

83. Biederman J, Mck E, Spencer T, et al. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006;11(5):390–396.

84. Wilens T, Kratochwil C, Newcorn J, Gao H. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child and Adolesc Psychiatry. 2006;45(2):149–157.

85. Wilson HK, Cox DJ, Merkel RL, Moore M, Coghill D. Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2006;21:797–807.

86. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–1904.

87. Novak SP, Kroult LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy. 2007;2:32.

88. Pilkington M, Cannatella A. Nonmedical use of prescription stimulants: age, race, gender, and educational attainment patterns. J Hum Behav Soc Environ. 2012;22(4):409–420.

89. Darredeau C, Barrett SP, Jardin B, Phil R. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol. 2007;22(8):529–536.
90. DeSantis A, Noar SM, Webb EM. Nonmedical ADHD stimulant use in fraternities. J Stud Alcohol Drugs. 2009;70(6):952–954.
91. Herman-Stahl MA, Krebs CP, Kroull LA, Heller DC. Risk and protective factors for nonmedication use of prescription stimulants and methamphetamine among adolescents. J Adolesc Health. 2006;39(3):374–380.
92. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095–1116.
93. Sweeney CT, Sembower MA, Ertischuk MD, Shiffman S, Schnoll SH. Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse. J Addict Dis. 2013;32(1):1–10.
94. Veliz P, Boyd C, McCabe SE. Adolescent athletic participation and nonmedical Adderall use: an exploratory analysis of a performance-enhancing drug. J Stud Alcohol Drugs. 2013;74(5):714–719.
95. Gordon S, Tulak F, Troncale J. Prevalence and characteristics of attention-deficit hyperactivity disorder symptoms who misuse prescription stimulants: results from a national multicohort study. J Adolesc Health. 2013;52(12):1272–1280.
96. Williams RJ, Goodale LA, Shay-Fiddler MA, Glotzer SP, Chang SY. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict. 2004;13(4):381–389.
97. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10:111.
98. McCabe SE, West B. Medical and nonmedical use of stimulants: results from a national multicohort study. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1272–1280.
99. Franke AG, Bonertz, CC, Christmann MM, et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry, 2011;44(2):60–66.
100. Jeffers A, Benotsch EG, Koester S. Misuse of prescription stimulants for weight loss, psychosocial variables, and eating disordered behaviors. Appetite. 2013;65:8–13.
101. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006;38(1):43–56.
102. McCabe SE, Teter CJ. Drug use related problems among nonmedical users of prescription stimulants: a web-based survey of college students from a Midwestern university. Drug Alcohol Depend. 2007;91(1):69–76.
103. Advokat CD, Guirdy D, Martino SP. Licit and illicit use of medications for attention-deficit hyperactivity disorder in undergraduate college students. J Am Coll Health Assoc. 2008;56(6):601–606.
104. Jardin B, Looby A, Earleywine M. Characteristics of college students with attention-deficit hyperactivity disorder symptoms who misuse their medications. J Am Coll Health Assoc. 2011;59(5):373–377.
105. Habibzadeh A, Alizadeh M, Malek A, Maghbooli L, Shoja MM, Ghabil K. Illicit methylphenidate use among Iranian medical students: prevalence and knowledge. Drug Des Devel Ther. 2011;5:71–76.
106. Tuttle JP, Scheurich NE, Ranseen J. Prevalence of ADHD diagnosis and nonmedical prescription stimulant use in medical students. Acad Psychiatry. 2010;34(3):220–223.
107. Emanuel RM, Freilson SL, Kashima KJ, Sanguino SM, Sievers FS, Lazarus CJ. Cognitive enhancement drug use among future physicians: findings from a multi-institutional census of medical students. J Gen Intern Med. 2013;28(8):1028–1034.
108. Bossaer JB, Gray JA, Miller SE, Enck G, Gaddipati VC, Enck RE. The use and misuse of prescription stimulants as “cognitive enhancers” by students at one academic health sciences center. Acad Med. 2013;88(7):967–971.
109. McNiel AD, Muzzin KB, DeWald JP, et al. The nonmedical use of prescription stimulants among dental and dental hygiene students. J Dent Educ. 2011;75:365–376.
110. White BP, Becker-Blease KA, Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J Am Coll Health. 2006;54(5):261–268.
111. Lensing MB, Zeimer P, Sandvik L, Opjordsmoen S. Adults with ADHD: use and misuse of stimulant medication as reported by patients and their primary care physicians. Atten Defic Hyperact Disord. 2013;5(4):369–376.
112. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health Assoc. 2006;54(5):269–278.
113. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health Assoc. 2005;53(6):253–262.
114. Herman-Stahl M, Krebs CP, Kroull LA, Heller DC. Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25. Addict Behav. 2007;32(5):1003–1015.
115. Moore D, Burgard D, Larson R, Fern M. Psychostimulant use among college students during periods of high and low stress: an interdisciplinary approach utilizing both self-report and unobtrusive chemical sample data. Addict Behav. 2014;39(5):987–993.
116. Lookath SJ, Dunne EM, Katz EC. Predictors of nonmedical use of prescription stimulants. J Psychoactive Drugs. 2012;44(1):86–91.
117. Janusis GM, Weyandt LL. An exploratory study of substance use and misuse among college students with and without ADHD and other disabilities. J Atten Disord. 2010;14(3):205–215.
118. Barrett S, Darredeau C, Bordy LE, Phil RO. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry. 2005;50(8):457–461.
119. Sepulveda DR, Thomas LM, McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students. J Pharm Pract. 2011;24(6):551–560.
120. Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovasc Disord. 2012;12:41.
121. Arria AM, O’Grady KE, Caldeira KM, Vincent KB, Wish ED. Nonmedical use of prescription stimulants and anlogesics: associations with social and academic behaviors among college students. J Drug Issues. 2008;38(4):1045–1060.
122. Ilieva I, Boland J, Farah MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropsychopharmacology. 2013;38:496–505.
123. Svetlov SL, Kobeisy FH, Gold MH. Performance enhancing, non-prescription use of Ritalin: a comparison with amphetamines and cocaine. J Addict Dis. 2007;26(4):1–6.
124. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26(10):1501–1510.
125. Lord S, Downs G, Furtaw P et al. Nonmedical use of prescription opioids and stimulants among student pharmacists. J Am Pharm Assoc. 2009;49(4):519–528.
126. Mansbach RS, Moore RA. Formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend. 2006;83(1):15–22.
127. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23:419–427.
128. Hartung CM, Caru WH, Cleveland CS, et al. Stimulant medication use in college students: comparison of appropriate users, misusers, and nonusers. Psychol Addict Behav. 2013;27(3):832–840.
129. Kroull LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray BM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84:135–143.
130. Clegg-Krayonok MM, McBean MM, Montgomery-Downs HE. Sleep quality and characteristics of college students who use prescription psychostimulants nonmedically. Sleep Med. 2011;12:598–602.
Pharmacological interventions for adolescents and adults with ADHD